Experimental substances with different molecular identities and limited human evidence.
Bottom line: Neither substance has been shown to be an effective routine treatment for injuries, and the sources do not show better outcomes when they are combined. They also do not support the popular claim that one works locally and the other systemically. [1–4]
| BPC-157 | TB-500 | |
|---|---|---|
| Identity | Experimental pentadecapeptide. [1] | Acetylated seven-residue thymosin beta-4 fragment identified as Ac-LKKTETQ. [3] |
| Human recovery benefit | Not established by the small uncontrolled reports. [1,2] | Not established for the fragment. [3,4] |
| Dose and injection site | No validated routine treatment dose or near-injury subcutaneous protocol in these sources. [1,2] | No validated human treatment dose or injection-site protocol in these sources. [3,4] |
| Safety | Limited safety information; FDA flags immune-reaction and impurity concerns. [4] | FDA reports no identified human exposure data for drug products containing the fragment and flags impurity and immune-reaction concerns. [4] |
tierA: {"tier":1,"label":"Small uncontrolled human reports"}
tierB: {"tier":1,"label":"Human treatment evidence not established"}
summary: BPC-157 has a small retrospective knee-pain report and a two-person intravenous pilot. Analytical TB-500 research identifies an acetylated fragment; full-length thymosin beta-4 trials are not trials of that fragment. [1–4]
trials: [{"name":"BPC-157 knee-pain report","peptide":"a","n":"16 contacted","finding":"Retrospective follow-up after joint injections; 12 received BPC-157 alone and four BPC-157 with TB4. No control group or standardized functional assessment. This does not establish tendon repair or a subcutaneous protocol.","pmid":"34324435"},{"name":"BPC-157 intravenous pilot","peptide":"a","n":"2","finding":"No adverse effects observed in this limited assessment. Too small to establish general or long-term safety.","pmid":"40131143"}]
The cited human evidence does not establish that distinction. Intra-articular BPC-157 research does not test injections into nearby subcutaneous tissue. [1]
A common name for a BPC-157 and TB-500 combination. The name does not establish safety, effectiveness or an appropriate dose.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
